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Abstract: Acromegaly is a rare disease characterized by excessive growth hormone secretion, 
usually from a pituitary tumor. Treatment options include surgery, medical therapy, and in some 
cases, radiation therapy. Current medical therapy consists of treatment with somatostatin analog 
medications or a growth hormone receptor antagonist. There are two somatostatin analogs cur-
rently in use, octreotide and lanreotide. Both are supplied in long-acting formulations and are of 
comparable biochemical efficacy. Lanreotide is supplied in a prefilled syringe and is injected into 
deep subcutaneous tissue. Studies have been conducted to assess the efficacy of self- or partner 
administration, and have demonstrated that injection of lanreotide can be accomplished reliably 
and safely outside a physician’s office. For patients who have achieved biochemical control with 
lanreotide, the FDA has recently approved an extended dosing interval. Selected patients may 
be able to receive the medication less frequently with injections of 120 mg administered every 
6 or 8 weeks. This review focuses on the use of lanreotide in the treatment of acromegaly, the 
safety and efficacy of the drug, and the benefits afforded to patients because of unique aspects 
of the delivery of lanreotide.
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Introduction
Acromegaly is a chronic, insidious disease caused by excess growth hormone (GH) 
secretion, usually from a pituitary adenoma. Uncontrolled disease is associated with an 
approximately 2–4 fold increased mortality1,2 and multiple comorbidities.3   Treatment 
of acromegaly consists of a combination of modalities including surgery, medical 
therapy, and radiation therapy.4,5 Medical therapy, either for adjuvant therapy or pri-
mary medical therapy, consists of somatostatin analogs or GH receptor antagonists. 
Somatostatin analogs act to decrease GH secretion from the pituitary adenoma or 
remnant tissue, thereby reducing insulin-like growth factor one (IGF-I) levels, and 
reducing signs and symptoms associated with acromegaly.
Many patients undergo surgery as their primary therapy; however, patients who pres-
ent with invasive tumors require medical therapy after non-curative surgery. Es  timated 
rates of surgical cure with an experienced surgeon depend on tumor size, and approxi-
mately 40% of all patients require some medication after primary   surgery.6 Somatostatin 
analogs induce biochemical control in approximately 50%–60% of treated patients.7 
The two drugs available in this class are long-acting injectable medications, octreotide 
(S  andostatin LAR, Novartis, Basel, Switzerland) and lanreotide (Somatuline Depot, Ipsen, 
Paris, France). Both medications are of comparable efficacy and have similar molecular 
structure and mechanisms of action.4 One key difference between these medications is 
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how the drugs are supplied and how this difference impacts the 
administration of the drugs. Another important difference is the 
recent FDA approval of an extended dosing interval between 
injections in patients controlled with lanreotide, making it 
possible to administer this medication less frequently, thereby 
reducing the cost of care for these patients.
This review focuses on the delivery system utilized by 
lanreotide and the benefits that this delivery system   provides. 
Prescribing information is discussed and elements of the 
delivery of this drug that provide benefit to patients and 
prescribers will be reviewed. This paper critically reviews 
the impact lanreotide has on treatment of acromegaly, the 
effect on quality of life, and the level of satisfaction garnered 
by patients using the medication.
Background
Acromegaly is a rare disease, with an incidence approximated 
at 3–4 cases per million per year,8 and estimated prevalence 
of 8.6 per 100,000 or higher.9,10 The onset is insidious with 
diagnosis often delayed for many years.11,12 Left untreated, 
the disease causes a significant increase in mortality, due 
primarily to cardiovascular and cerebrovascular disease.1,2 
Treatment of acromegaly improves the increased risk of 
mortality, decreases comorbidity, and improves quality 
of life. Reduction in serum GH levels and normalization of 
serum IGF-I levels are associated with a return of mortality 
risk to that of a control population.13,14
The goals of therapy include control of GH secretion, 
control of the tumor mass, reduction in associated comor-
bidities and symptoms of acromegaly, and preservation of 
normal pituitary function. Treatment modalities currently 
employed include surgery, medical therapy, and radia-
tion therapy. Recent advances have furthered the field of 
acromegaly treatment, including improvements in surgical 
techniques incorporating endoscopic instruments and tech-
niques employed for stereotactic radiation, as well as novel 
medications and medication delivery systems.
Surgical resection of a GH secreting pituitary tumor is 
the primary treatment of choice for most of the patients with 
acromegaly.15 In experienced hands, the surgical cure rate 
is high for microadenomas (maximum diameter , 10 mm), 
but the cure rate declines when tumors are invasive or for 
macroadenomas (diameter . 10 mm).6 When surgery is 
successful, as measured by normalization of elevated IGF-I, 
and suppression of GH by a glucose load, patients continue 
to require monitoring for tumor recurrence but do not need 
further treatment of excess growth hormone. If surgery is 
not curative, further treatment is required.
There are multiple medications available to treat 
ac  romegaly. Dopamine agonist medications, bromocriptine 
and cabergoline, have been used to treat acromegaly and work 
by suppressing GH secretion from the somatotroph adenoma. 
Somatostatin analogs suppress GH secretion and have been 
shown to have effects on tumor shrinkage. The GH receptor 
antagonist pegvisomant is the only drug in its class,16 and 
effectively blocks the effects of GH at the level of the GH 
receptor, reducing IGF-I levels and controlling symptoms.17 
Use of these medications in combination has also been 
published, with increased efficacy shown with combination 
therapy of dopamine agonists and somatostatin analogs,18 
as with combined use of pegvisomant and so  matostatin 
analogs.19,20
Treatment with somatostatin analogs is generally well 
tolerated, efficacious in approximately 60% of patients, and 
has effects on both biochemical parameters (GH and IGF-I 
secretion) as well as effects on tumor mass.21 Somatostatin 
analogs may be used as adjuvant therapy after pituitary sur-
gery or as primary therapy in selected patients.15 Somatostatin 
analog medications have been shown to have positive effects 
on symptoms, GH secretion, serum IGF-I levels, tumor 
size, comorbidities and effects of chronic GH secretion. 
However, many patients treated with somatostatin analogs 
will not normalize their GH and IGF-I levels, and require 
further treatment.
In addition to medical therapy, radiation therapy – 
including conventional radiation, stereotactic conventional 
radiation therapy, gamma knife therapy, proton beam – has 
been used to control tumor mass and reduce GH secretion.22 
Use of radiation in the treatment of patients with acromegaly 
has been associated with an increased rate of mortality and 
cerebrovascular events.23,24 Despite the adverse effects that 
limit its appeal, radiation therapy remains an integral part of 
treatment for challenging patients with acromegaly. Its use 
varies in different treatment centers, with some reserving 
its use for only the most difficult cases, while others use the 
treatment more frequently in lieu of costly, lifelong medical 
treatment.
Monitoring patients with acromegaly usually entails 
regular assessments of serum GH and IGF-I levels, MRI 
surveillance, and careful regular assessments and treat-
ments of comorbidities associated with acromegaly. 
Chronic GH excess can have profound effects on metabo-
lism, the cardiovascular system, and joints, making regular 
assessment of glucose metabolism, cardiovascular disease, 
and arthritis a lifelong component of acromegaly care. 
Furthermore, effects on sleep apnea and the increased 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
74
CarmichaelPatient Preference and Adherence 2012:6
risk of developing colon polyps requires assessment for 
ongoing sleep apnea and regular colonoscopy even when 
biochemical control or cure is attained. Safety monitoring 
of medical therapy requires MRI surveillance and assess-
ment of transaminase levels for pegvisomant, but no regular 
safety surveillance is required specifically for somatosta-
tin analogs. Physicians should be aware of potential side 
effects of cholecystitis or gallstone formation, however, 
and assess complaints consistent with these side effects 
with gall bladder ultrasound.
Drug profile
Mechanism of action
Lanreotide is a synthetic octapeptide that is an analog of 
the biologically active portion of somatostatin, a 14-amino 
acid peptide that binds to somatostatin receptors (SSTR). 
There are at least five SSTR subtypes that are g-protein 
coupled receptors with seven trans-membrane span-
ning domains.25 Lanreotide has a high affinity to SSTR 
su  btype 2 (SSTR2) and SSTR subtype 5 (SSTR5). These 
receptor subtypes regulate GH secretion from pituitary 
somatotroph cells and their activity is retained in most 
pituitary ad  enomas secreting GH. Binding of lanreotide to 
the SSTR2 and SSTR5 results in decreased GH secretion 
from the so  matotroph tumor.25
Since lanreotide is available in multiple formulations 
worldwide, and the medical literature is replete with mul-
tiple studies investigating the safety, efficacy, and use of 
these formulations, reviewing the use of this medication 
can be complex. Lanreotide was initially supplied as a 
prolonged release medication that utilized a micropar-
ticle vehicle to sustain the actions of lanreotide once 
administered. This formulation is known as the prolonged 
release (PR) or sustained release (SR) formulation. The 
PR formulation is administered every 7–14 days in a fixed 
dose and demonstrates good efficacy and tolerability in 
treatment of acromegaly.26 Later, lanreotide became avail-
able in a preparation that delivered more sustained levels 
of drug through a depot formulation. This formulation is 
a supersaturated gel of lanreotide and water only, without 
other incipients. This formulation is in current use in the 
US and worldwide. Outside the US, it is known as the auto-
gel formulation, and in the US it is known as Somatuline 
depot formulation. Thus, many studies conducted prior 
to the drug’s release in the US or outside the US describe 
this medication as “lanreotide autogel,” while studies 
conducted after its FDA approval in the US may refer to 
it as “lanreotide depot formulation” (Table 1).35–47
Pharmacodynamics
Much of the knowledge regarding the pharmacokinetics and 
pharmacodynamics of the depot formulation is derived from 
clinical experiments using lanreotide in the PR formulation 
and the autogel formulation, as well as pharmacokinetic data 
derived from various computer models.27
Similar to native somatostatin, lanreotide exhibits 
endocrine effects throughout the body through coupling 
with SSTRs.25 The primary pharmacodynamics effect is the 
reduction of GH secretion, resulting in decreased production 
of IGF-I in various tissues. Somatotroph pituitary adenomas 
predominately express SSTR2 and 5, and increased affinity 
for these subtypes by synthetic somatostatin receptor ligands 
such as lanreotide provide for the primary pharmacodynamics 
effect of reduction in GH secretion. SSTRs are also expressed 
throughout the gastrointestinal tract and pancreas, account-
ing for the known adverse effects related to gastrointestinal 
motility.28 Lanreotide inhibits basal motilin, gastric inhibitory 
peptide, and pancreatic polypeptide secretion. Postprandial 
secretion of pancreatic polypeptide, gastrin, and cholecys-
tokinin are inhibited by lanreotide, and in healthy subjects 
postprandial insulin secretion is delayed, resulting in tran-
sient mild glucose intolerance.29 Other non-pituitary effects 
observed include increased amylase secretion in healthy 
individuals, and delayed postprandial bicarbonate secretion 
in the duodenum, resulting in reduction in gastric acidity.29
Pharmacokinetics
The pharmacokinetic profile of lanreotide depot has 
been evaluated in healthy subjects and patients with 
acromegaly.27,30,31 Half-life, as determined by injection 
in healthy volunteers after a single administration, was 
21–22 days.30 During administration of fixed doses every 
28 days over a 4 month clinical trial, pharmacokinetics were 
established after a single dose and at steady state.31 The 
depot formulation showed linear pharmacokinetic profiles 
in three different dosages (60, 90, and 120 mg) after a single 
injection and repeated administration (Figure 1). There was 
no apparent burst effect after administration and a stable 
linear release profile was seen over the following 28 days. 
Minimum and maximum concentrations and area under 
the curve followed expected dose proportionality. Based 
on population pharmacokinetics, and software-assisted 
modeling of drug disposition, minimum effective levels of 
lanreotide were found with a dose of 120 mg 56 days after 
injection.27,32 With this information, the possibility of extend-
ing the interval between injections was suggested. Extended 
dosing intervals have recently been FDA approved.
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Therapeutic efficacy
Therapeutic efficacy for lanreotide in the PR formulation has 
been well established, and since the advent of the autogel 
or depot formulation, the efficacy of the newer formulation 
has been increasingly demonstrated in multiple clinical trials. 
The following review will focus only on trials involving the 
currently available depot or autogel formulation, used alone 
in the treatment of acromegaly. Clinical trials where efficacy 
of the drug was the primary endpoint will be reviewed.
To date, while there have been several small studies con-
ducted observing clinical endpoints in treatment of acromeg-
aly with various forms of lanreotide and octreotide, no study 
has been large enough or adequately powered to demonstrate 
superiority of one drug over another. The efficacy rates, in 
terms of biochemical endpoints, of all somatostatin analog 
treatments vary among multiple clinical trials. For adjuvant 
therapy, GH and IGF-I control ranges from approximately 
30%–75%, whereas primary medical therapy for GH and 
IGF-I control ranges from approximately 40%–75%.33
Two systematic reviews of the use of somatostatin ana-
logs, including lanreotide, have been published.26,34 The first 
evaluated 44 trials of octreotide LAR and lanreotide PR, 
and did not include data on the autogel formulation.26 The 
second critical review of somatostatin analog use included 
large studies using octreotide, octreotide LAR, lanreotide 
PR, and lanreotide autogel/depot formulation.34 This analysis 
provides a substantial overview of the use of these medica-
tions in the treatment of acromegaly, and suggests that the 
two long-acting preparations, octreotide LAR and lanreotide 
autogel, are comparable in their efficacy. Establishing any 
superiority of one medication over another would require a 
randomized, controlled trial.
Table 1 summarizes the biochemical efficacy endpoints 
for several studies evaluating the use of lanreotide autogel/
depot in the treatment of acromegaly.35–47 Trials listed in the 
table specifically investigated biochemical outcomes and 
published rates of GH and IGF-I control. Additional trials 
have been reported examining effects of lanreotide on out-
comes such as tumor size, cardiovascular effects, and glucose 
metabolism.40,48,49 Most of the clinical trials investigating 
the efficacy of lanreotide have been conducted on subjects 
who received treatment of one form or another (surgical, 
radiation, or medical) prior to study entry. Specifically, many 
studies evaluated the efficacy of lanreotide after transitioning 
from either lanreotide as supplied in the PR formulation or 
from octreotide LAR. Hence, these studies, and the efficacy 
rates they quote, need to be evaluated with the knowledge 
that there may be a selection bias in the response rates as 
published. Similarly, few studies have been conducted with 
randomization or stratification.
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Based on published studies, dose titration does appear 
to improve the efficacy rates in patients treated with 
la  nreotide. In addition, the majority of patients who have 
par  ticipated in these studies required escalation of the dose up 
to the m  aximum of 120 mg every 28 days. A study evaluating 
alternative dosing schemes investigated whether decreasing 
the interval for subjects requiring a dose higher than 120 mg 
every 28 days found no further improvement with a dose of 
120 mg every 21 days.50
Tolerability/Safety
The safety and tolerability of lanreotide has been addressed 
by multiple studies as well as post marketing surveillance.29 
The drug is well tolerated and has been used for many years 
in treatment of acromegaly. Pooled adverse events reported 
at .5% in 416 patients from seven clinical trials are presented 
in Table 2. The most common side effects are gastrointestinal 
complaints including diarrhea, abdominal pain, loose stools, 
flatulence, nausea, constipation, and vomiting. In a placebo-
controlled trial comparing different doses of lanreotide, the 
gastrointestinal symptoms were reported in higher frequency 
with higher doses.29 Cholelithiasis and injection-site reactions 
are also commonly observed. Gastrointestinal complaints 
occur more severely and frequently when the medication 
is initiated, and become less bothersome over the course of 
treatment. Cholelithiasis is observed in subjects receiving 
somatostatin analogs, and has been observed as biliary sludge 
and asymptomatic stones more frequently than symptom-
atic biliary obstruction. Injection site reactions, including 
injection site pain, mass, and induration were reported at a 
higher frequency at the beginning of therapy, and decreased 
in incidence as treatment progressed.29
Changes in blood glucose levels (hyperglycemia, 
hy  poglycemia, or diabetes) were reported in 14% of subjects 
in seven clinical trials with 7% related to the study drug.29 
So  matostatin analogs are known to delay insulin secretion 
after a glucose load, which may alter blood glucose metabo-
lism and have a causative role in altered glucose metabolism. 
Sinus bradycardia was the most commonly reported cardiac 
adverse event, but associations with the study drug could not 
be clearly established due to the high prevalence of cardiac 
disease in these subjects.29
Patient adherence and satisfaction
Self- or partner injection
One of the key elements to patient satisfaction is ease of 
administration and access to medication. The advent of an 
injectable medication in a prefilled syringe has improved 
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access to medication, especially for those who need to travel 
to obtain monthly injections and find this is a hardship. 
Lanreotide, since it does not require reconstitution, can be 
injected by a trained individual (either the patient or a trusted 
“partner”) without concern of variability in drug preparation. 
Self-administration has been widely approved in European 
countries and since there is no statement requiring administra-
tion of the drug by a medical professional in the prescribing 
information, the medication can be administered outside the 
confines of the medical office or hospital.
Two multicenter studies have been conducted to evalu-
ate the safety and efficacy of self- or partner injection, 
one in the UK and another in the US.51,52 In the UK study, 
30 subjects were recruited to assess the ability of patients 
or their partners to safely and reliably administer multiple 
doses of the medication in an unsupervised setting.52 The 
primary endpoint was the proportion of subjects who were 
able to successfully administer the medication throughout 
the study. Multiple centers throughout the UK were involved 
in the clinical trial, which was an open-label controlled 
study of 36 months. In this study, patients self-selected at 
the screening visit whether to receive lanreotide as admin-
istered by a health care professional (control subjects) or 
by either themself or a partner (test subjects). Doses were 
not titrated during the study and stable doses (over at least 
4 months) were required prior to study entry. Test subjects 
were trained to inject the lanreotide at the baseline visit and 
performed occasional supervised injections for training as 
needed. Once trained, the individuals performed home injec-
tions, unsupervised, for the duration of the trial. There were 
15 subjects in the test group and 15 in the control group. 
Subjects in the test group were younger and more likely 
to have undergone pituitary surgery. Prior treatment with 
somatostatin analogs was longer in duration for the control 
group. All test su  bjects were quickly deemed suitable for 
home injection (by partner or self) after one training session. 
Nearly all subjects in the test group (93%) were able to suc-
cessfully administer the injection at home. The one subject 
who did not meet the endpoint criteria had an increase in 
mean GH to .5 ng/mL at study end. GH and IGF-I control 
was maintained during the trial, however, as assessed at 
the interim visit. Two subjects (one in the test group and 
one in the control group) did not demonstrate controlled 
biochemistry at study end. No subjects withdrew from the 
study. Pain associated with the injection was not reported 
any worse in the partner or self-administered group.
The US study differed in its methods but also explored the 
ability of subjects to self- or partner administer lanreotide.51 
Table 2 Adverse reactions at an incidence .5% reported in selected clinical studies
System organ class Number and percentage of patients
Pivotal studies 1 and 2 
(N = 170)
Overall pooled data 
(N = 416)
N % N %
Patients with any adverse reactions 
Gastrointestinal disorders
157 
121
92 
71
356 
235
86 
57
  Diarrhea 81 48 37 155
  Abdominal pain 34 20 19 79
  Nausea 15 9 11 46
  Constipation 9 5 8 33
  Flatulence 12 7 7 30
  vomiting 8 5 7 28
  Loose stools 16 9 6 23
Hepatobiliary disorders 53 31  99 24
  Cholelithiasis 17 45 20 85
General disorders and administration site conditions 51 30 91 22
  (injection site pain/mass/induration/nodule/pruritus) 17 28 37 9
Musculoskeletal and connective tissue disorders 44 26 70 17
  Arthralgia 17 10 30 7
Nervous system disorders 34 20 80 19
  Headache 9 5 30 7
Cardiac system disorders
  Sinus bradycardia 12 7 13 3
  Hypertension 11 7 20 5
Anemia 12 7 14 3
Note: information from Somatuline Depot Prescribing information.29
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This was a 6-month open-label single-arm study, conducted 
at multiple centers in the US. While the UK study required 
stable dosing of lanreotide 4 months prior to entry, the US 
study enrolled subjects who opted to switch from prior 
therapy with Sandostatin LAR (switch patients) or were 
either drug naïve (naïve patients) or not currently receiving 
treatment (no medication for 4 months prior to entry). These 
patients were collectively described as “other” patients. 
D  osing of the lanreotide at study entry depended upon the 
dose of prior therapy (if any) or was set at 90 mg monthly 
for naïve subjects. Dosing was adjusted 16 weeks after study 
entry based on serum IGF-I levels and symptoms.
At the baseline visit, patients were given the option of 
self-administration or partner administration. Subjects and 
partners were trained, and study staff utilized a questionnaire 
to assess competency on a monthly basis during the first 
3 months of the study. A diary and a patient questionnaire 
assessed the patients’ symptoms throughout the study period. 
As with the UK study, the primary endpoint was the percent-
age of patients or partners who were able to successfully 
administer lanreotide without supervision of a health care 
professional. Fifty-nine patients were recruited and seven of 
these were withdrawn from the clinical trial. Seventy percent 
of subjects in the trial preferred to self-inject. All subjects 
were assessed as being competent to self- or partner admin-
ister their medications by week 4 and throughout the study. 
A significant number of switch patients found their injections 
to be less painful than those of Sandostatin LAR (50% vs 
25%) and switch patients found the lanreotide injection very 
convenient compared to Sandostatin LAR (75% vs 18%; 
P = 0.0002). Most patients who switched to lanreotide for the 
trial reported that they preferred lanreotide over Octreotide 
LAR for future use (81% vs 12%; P = 0.0001)
Control, measured by serum IGF-I level, was achieved in 
the majority of switch patients at the study end. At baseline, 
84% of switch patients entered the study with controlled 
IGF-I, and 94% achieved normal IGF-I values at study end. 
Forty-three percent of other patients achieved a normal IGF-I 
at study end. Symptoms were either improved or similar in 
switch and other patients.
The results of these studies indicate that patients are able 
and willing to self-inject or have a partner assist with injec-
tions outside a medical office. The studies confirm that the use 
of the prefilled syringe, which is ready for injection without 
the requirement drug reconstitution, offers convenience 
without sacrificing disease control. The use of lanreotide 
by a non-health care professional is aided by the fact that 
the medication need not be injected into the muscle but is 
intended for deep subcutaneous injection. This allows for a 
short needle, thus making the home injection process less 
intimidating than an intramuscular injection.
Quality of life and symptom control
Quality of life and symptom control have only been 
reported briefly in selected studies.35,40–42,51,53 Most studies 
conducted with lanreotide depot had very few p  articipants 
withdraw due to adverse effect or lack of efficacy.29 
Sy  mptoms improved over the course of all studies to vary-
ing degrees. Significant improvements have been reported 
for hyperhidrosis,40,42 arthralgias,40 headache,42 and total 
symptoms.35,51 Quality of life, as assessed by a specific 
questionnaire for acromegaly, was used but demonstrated 
no improvement in three separate treatment arms from study 
entry to study end.53
Dosage and administration
Somatuline depot is supplied in 60 mg, 90 mg, and 120 mg 
doses. The dosing is volume dependent, not concentration 
dependent, so increasing doses require larger volumes 
ranging from 0.3 to 0.5 cc. The prefilled syringe requires 
refrigeration and needs to warm to room temperature prior 
to injection.
The 90 mg dose should be used initially as treatment for 
acromegaly, given every 4 weeks, for 3 months. Ac  cording to 
the prescribing information, the dose should then be titrated 
according to results of serum GH and IGF-I m  easurements. 
Patients who remain uncontrolled, with ongoing clinical 
symptoms of active acromegaly and serum IGF-I levels 
elevated above age-matched normal levels, and with a serum 
GH level .2.5 ng/mL, should increase the dose to 120 mg 
administered every 4 weeks. Based on the current prescrib-
ing information, it is recommended that patients who are 
symptomatically controlled and have a normalized serum 
IGF-I level with a serum GH level between 1 ng/mL and 
2.5 ng/mL maintain a dose of 90 mg administered every 
4 weeks. Patients and clinicians who prefer to adhere to 
clinical guidelines for criteria of disease control54 may wish 
to increase the dose to 120 mg every 4 weeks. If the patient’s 
symptoms are controlled, the IGF-I is normalized, and the 
serum GH level is below 1 ng/mL, then the dose of Somatu-
line can be reduced to 60 mg every 4 weeks. Recent guide-
lines regarding the monitoring of patients with acromegaly 
and the criteria for disease control recommend the use of 
random, single GH levels in patients receiving somatostatin 
analogs,55 as the GH level obtained after glucose suppression 
has limited utility.56
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One aspect of approved dosing unique in its approach 
toward the treatment of acromegaly with somatostatin ana-
logs is the ability to utilize an extended dosing interval. In 
addition to the guidelines outlined above, patients who have 
achieved disease control with 60 mg or 90 mg administered 
on a monthly basis can extend the time between injections to 
every 6–8 weeks with an increase in the dose of lanreotide 
to 120 mg. Studies have been conducted to investigate the 
efficacy, acceptability, and cost effects of extending the 
dosing interval beyond monthly.50,53 One study, conducted 
in Germany, enrolled subjects who were previously treated 
with octreotide LAR doses of 10 mg, 20 mg, and 30 mg 
monthly and switched them to lanreotide depot 120 mg at 
intervals of every 56, 42, and 28 days, respectively.53 Doses 
were titrated after three injections based on the serum IGF-I 
levels. Thirty-seven patients were enrolled and 33 subjects 
completed the study. The intervals set at the beginning of 
the study remained the same for most subjects in the study 
(71%). For 5 subjects the interval needed to be shortened to 
28 days and two patients were able to increase their interval 
during the study period. Sixty percent of subjects entered the 
study with biochemical disease control by IGF-I and a similar 
number (63%) achieved disease control at study end. Subjects 
who were assigned a more frequent dosing schedule were 
on higher doses of somatostatin analog medication prior to 
study entry. These patients may have been more resistant to 
this class of medications in general and consequently showed 
the lowest rates of normalization (47%) at study entry and 
study end. However, subjects in the longest interval-dosing 
arm, receiving medication every 56 days, had rates of disease 
control of 86% at study entry and study end. Furthermore, 
mean serum IGF-I levels declined throughout the duration 
of the study in the 56-day interval arm. Quality of life was 
measured using the Acromegaly Quality of Life question-
naire and demonstrated no significant change in quality of 
life across all treatment groups.53 These results demonstrate 
that extended dosing is effective at achieving similar rates 
of control in subjects who have demonstrated that they are 
responders to the somatostatin analog class of medications. 
Investigators judged the injections with lanreotide to be easier 
than using octreotide LAR and patients preferred receiving 
their injections less frequently.53
Another study approached extended dosing in a dif-
ferent way.50 By increasing the interval in nine subjects, 
and only increasing the dose if disease control was not 
optimized as measured by combined assessment of GH 
and IGF-I, they found that some patients using the 60 mg 
(n = 3), the 90 mg dose (n = 2), or the 120 mg dose (n = 2) 
could increase the interval between shots to every 6 weeks 
and maintain disease control over a 24-week period. This 
reduced the overall dose and cost of administration. S  ubjects 
had previously enrolled in a separate study switching from 
octreotide LAR to lanreotide35 and, after being treated 
with lanreotide for 24 weeks, they enrolled in this study 
to evaluate the efficacy of extended dosing. Patients were 
biochemically controlled at baseline and maintained control 
with a lower drug requirement in 7/9 subjects. Symptom 
scores did improve during the study but this difference was 
not statistically significant.
Place of lanreotide in the treatment 
of acromegaly
Lanreotide is one of two commercially available somatostatin 
analogs used for treatment of acromegaly. Both medications 
are effective, well tolerated, and are the primary drugs used for 
medical treatment of acromegaly. Use of one formulation over 
another depends on many factors including insurance coverage, 
physician preference, comfort level, and patient preference. 
Certain aspects of lanreotide, including the drug delivery 
system, ease of administration, and potential for an extended 
dosing interval between injections for those who are well con-
trolled on 90 mg or 60 mg doses may have an impact on the 
choice of drug when treating patients with acromegaly.
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